Novo Nordisk Announces Major Price Reductions for Obesity and Diabetes Drugs in the U.S.

Novo Nordisk Announces Major Price Reductions for Obesity and Diabetes Drugs in the U.S.

Novo Nordisk has announced a significant price reduction for its obesity and diabetes drugs in the U.S. The company plans to cut the monthly list prices of popular medications like Wegovy, Ozempic, and Rybelsus by up to 50% starting in 2027. This move aims to make these treatments more affordable for patients with insurance coverage. The new list price for these drugs will be $675 per month, down from the current prices of around $1,350 for Wegovy and $1,027 for the diabetes drugs.

Novo's price cuts are specifically targeting insured patients whose out-of-pocket costs are tied to list prices, such as those with high-deductible health plans or co-insurance benefit designs. By reducing the list prices, the company hopes to address the needs of patients who face financial barriers to accessing these medications. This strategic decision also positions Novo Nordisk to compete more effectively with Eli Lilly, a key player in the GLP-1 market. While Lilly has a strong presence in the market, Novo's price adjustments could help level the playing field.

Jamey Millar, Novo Nordisk's head of U.S. operations, emphasized the importance of improving access to these medications for patients and payers. The company's decision to lower list prices reflects a response to the demand for more affordable healthcare options. By reducing the cost barriers associated with these drugs, Novo aims to ensure that more patients can benefit from the value of Wegovy and Ozempic. This commitment to accessibility and affordability underscores Novo Nordisk's dedication to supporting patient health and well-being.